西妥昔单抗
结直肠癌
克拉斯
医学
肿瘤科
内科学
癌症
成本分析
成本效益分析
成本效益
风险分析(工程)
运筹学
数学
作者
Ruihong Yao,Yao Yao,Teng Xue,Yao Jin,Shangwei Guan,Mei Dong,Tong Liu
标识
DOI:10.1080/14737167.2025.2521439
摘要
OBJECTIVES: from the perspective of healthcare payers in the USA. METHODS: An economic evaluation utilizing a 3-state partitioned survival model assessed the cost-effectiveness of adagrasib plus cetuximab versus adagrasib monotherapy. The Kaplan-Meier curves for overall survival (OS) and progression-free survival (PFS) from a clinical trial were digitally extracted, and the Log-Logistic model was employed at the end of the trial to extrapolate the long-term survivals. RESULTS: . CONCLUSION: in the USA.
科研通智能强力驱动
Strongly Powered by AbleSci AI